Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s279, 2023. DOI: 10.25251/skin.7.supp.279. Disponível em: https://skin.dermsquared.com/skin/article/view/2389. Acesso em: 1 may. 2026.